Latest news with #Phytanix
Yahoo
31-05-2025
- Business
- Yahoo
Protagenic & Phytanix Merge in All-Stock Move, Sparking Retail Frenzy
Protagenic Therapeutics (NASDAQ: PTIX) just pulled off a biotech plot twist worthy of a season finale. On May 19, shares skyrocketed over 240% following news of an all-stock merger with Phytanix Bio, forming a new entity: Phytanix, Inc. It's a full pipeline overhaul, and not just a name change. The new Phytanix has six drug candidates: PT-00114, a Phase I/IIa peptide targeting stress-related disorders, and five preclinical assets, including PHYX-001, a potassium channel modulator, and several cannabinoid-based compounds. They're eyeing big markets like obesity and CNS disorders, stepping into arenas dominated by heavyweights like Novo Nordisk (NYSE:NVO). A closeup of pills in a pharmacy, representing the high quality medications of the company. Phytanix shareholders will own about 65% of the combined company, with Protagenic investors owning the remaining 35%. The deal includes common stock, convertible preferred shares, and warrants, pending Nasdaq stockholder approval requirements. With team members from GW Pharma (think Epidiolex and Sativex), Phytanix brings seasoned CNS expertise. However, most assets are in early stages, meaning substantial development ahead. In summary, Protagenic's leap into Phytanix territory is bold. Whether it's a biotech Cinderella story or a cautionary tale depends on how the next chapters unfold. While we acknowledge the potential of PTIX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PTIX and that has 100x upside potential, check out our report about the . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. Sign in to access your portfolio
Associated Press
21-05-2025
- Business
- Associated Press
Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the 'Company') announced today that warrant exchanges and exercises over the last four trading days have generated $3.1 million in cash. The proceeds will fund working-capital needs and advance the Company's peptide-based drug candidates for stress-related and central-nervous-system disorders. This financing comes as Protagenic executes on its previously announced business combination with Phytanix Bio Inc. (May 19, 2025). The combination has brought together six complementary drug programs spanning stress disorders, epilepsy, obesity, and other indications under one company. About Protagenic Therapeutics, Inc. Protagenic Therapeutics (Nasdaq: PTIX) is pioneering peptides for stress-related disorders. For more information, visit About Phytanix Bio Inc. Phytanix Bio is an innovative pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and 'cannabinoid-like' molecules. For more information, visit Forward-Looking Statements: This press release contains forward-looking statements concerning Protagenic Therapeutics' product candidates and clinical trial plans. These statements are subject to various risks and uncertainties. Investors are urged to exercise caution and not place undue reliance on these forward-looking statements. Company Contact: Alexander K. Arrow, MD, CFA Chief Financial Officer Protagenic Therapeutics, Inc. 149 Fifth Ave, Suite 500, New York, NY 10010 Tel: 213-260-4342 Email: [email protected] SOURCE: Protagenic Therapeutics, Inc. press release
